Blueprint Medicines COO Christina Rossi sells shares worth $216,075

CAMBRIDGE, MA— Blueprint Medicines Corp (NASDAQ:BPMC), a $5.8 billion market cap biotechnology company, saw Chief Operating Officer Christina Rossi recently sell 2,274 shares of the company’s common stock. The shares were sold on March 24, 2025, at an average price of $95.02, resulting in a total transaction value of $216,075. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with analysts setting price targets ranging from $83 to $169.

This sale was conducted under a trading plan adopted on August 27, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Post-transaction, Rossi retains ownership of 69,266 shares in Blueprint Medicines.

The sale was executed in multiple transactions, with prices ranging from $95.00 to $95.06 per share. Rossi has committed to providing detailed information regarding the specific number of shares sold at each price upon request.

In other recent news, Blueprint Medicines has been the focus of multiple analyst reports, highlighting the company’s financial prospects and drug development pipeline. Jefferies initiated coverage with a Buy rating and a $135 price target, citing the potential success of Ayvakit, especially after its label expansion to include ’indolent’ systemic mastocytosis, which constitutes a significant market opportunity. Wolfe Research also expressed optimism with an Outperform rating, predicting profitability and cash-flow positivity by late 2026, driven by Ayvakit’s performance. Scotiabank (TSX:BNS) set a price target of $150, emphasizing the underappreciated value of Blueprint’s systemic mastocytosis franchise and the potential of their drug elenestinib.

Morgan Stanley (NYSE:MS) resumed coverage with an Equalweight rating and a $100 target, noting Ayvakit’s steady growth but expressing caution about long-term revenue expectations for the systemic mastocytosis franchise. Citizens JMP reaffirmed its Market Outperform rating with a $125 price target, based on anticipated sales of Ayvakit reaching $700 million by 2025 and the promising development of BLU-808. Analysts are particularly interested in the upcoming proof of concept trials for several conditions, which could significantly impact the company’s stock value.

The various ratings and targets reflect a mix of confidence and caution among analysts regarding Blueprint Medicines’ future. The company’s efforts to enhance physician and patient awareness, expand its salesforce, and initiate reimbursement outside the United States are seen as strategic moves to bolster Ayvakit’s market presence. Blueprint Medicines’ focus on its drug development pipeline, particularly Ayvakit and BLU-808, remains central to its strategy to deliver value to shareholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.